Back to search

Article

Therapeutic Benefits of Recombinant Alpha1-Antitrypsin IgG1 Fc-Fusion Protein in Experimental Emphysema

2021-02-09

Abstract excerpt

<title>Abstract</title> <p>BackgroundAlpha-1 antitrypsin (AAT) is a major serine protease inhibitor. AAT deficiency (AATD) is a genetic disorder characterized by early-onset severe emphysema. In well-selected AATD patients, therapy with plasma-derived AAT (pAAT), “augmentation therapy”, provides modest clinical improvement but is perceived as cumbersome with weekly intravenous infusions. Using mouse models of emp...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
648c911a-c678-52df-86b3-6ab814e40e97
DOI
10.21203/rs.3.rs-180870/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Therapeutic Benefits of Recombinant Alpha1-Antitrypsin IgG1 Fc-Fusion Protein in Experimental EmphysemaDOI 10.21203/rs.3.rs-180870/v1
Select a neighboring publication to make it the new centre.